comparemela.com
Home
Live Updates
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress : comparemela.com
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data...
Related Keywords
United States
,
Beijing
,
China
,
San Diego
,
California
,
American
,
Richard Waldron
,
Mecbotamab Vedotin
,
Ozuriftamab Vedotin
,
Bruce Mackle
,
Nasdaq
,
Rare Cancers Congress
,
Bioatla Inc
,
American Association For Cancer Research
,
Exchange Commission
,
Lifesci Advisors
,
Office Of Orphan Products Development
,
Conditionally Active Biologic
,
Chief Executive Officer
,
Operational Updates
,
Rare Cancers
,
Rare Cancers Congress March
,
Scientific Meeting March
,
American Association
,
Cancer Research
,
Conditionally Active Biologics
,
Meeting April
,
Conditional Active Biologic
,
Full Year
,
Orphan Products Development
,
Orphan Drug Designation
,
Annual Report
,
Sci Advisors
,
comparemela.com © 2020. All Rights Reserved.